Ireland’s Health Service Executive (HSE) Drugs Group convened to discuss the potential inclusion of the Mounjaro injection on national healthcare schemes, but a decision has been postponed. Further meetings are expected as the HSE meticulously assesses both the financial implications and clinical evidence supporting the drug’s efficacy. The delay means patients in Ireland will continue to wait for potential public access to Mounjaro. The HSE is carefully evaluating the cost-benefit ratio before committing to funding the treatment. No timeline has been provided for when a final decision regarding Mounjaro’s availability in Ireland will be reached. This process underscores the complexities of introducing new medications into the Irish healthcare system.